These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 12416544)
1. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. Patchell RA; Regine WF; Ashton P; Tibbs PA; Wilson D; Shappley D; Young B J Neurooncol; 2002 Oct; 60(1):37-42. PubMed ID: 12416544 [TBL] [Abstract][Full Text] [Related]
2. Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial. Sultan AA; Jerjes W; Berg K; Høgset A; Mosse CA; Hamoudi R; Hamdoon Z; Simeon C; Carnell D; Forster M; Hopper C Lancet Oncol; 2016 Sep; 17(9):1217-29. PubMed ID: 27475428 [TBL] [Abstract][Full Text] [Related]
3. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD; Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. White E; Bienemann A; Taylor H; Hopkins K; Cameron A; Gill S Contemp Clin Trials; 2012 Mar; 33(2):320-31. PubMed ID: 22101221 [TBL] [Abstract][Full Text] [Related]
5. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain. Varveris H; Petinelli E; Stratakis J; Mazonakis M Oncol Rep; 2008 Feb; 19(2):447-55. PubMed ID: 18202794 [TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Lassman AB; Pugh SL; Gilbert MR; Aldape KD; Geinoz S; Beumer JH; Christner SM; Komaki R; DeAngelis LM; Gaur R; Youssef E; Wagner H; Won M; Mehta MP Neuro Oncol; 2015 Jul; 17(7):992-8. PubMed ID: 25758746 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964 [TBL] [Abstract][Full Text] [Related]
10. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Grossman SA; Hochberg F; Fisher J; Chen TL; Kim L; Gregory R; Grochow LB; Piantadosi S Cancer Chemother Pharmacol; 1998; 42(2):118-26. PubMed ID: 9654111 [TBL] [Abstract][Full Text] [Related]
11. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792 [TBL] [Abstract][Full Text] [Related]
13. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. Whittle JR; Lickliter JD; Gan HK; Scott AM; Simes J; Solomon BJ; MacDiarmid JA; Brahmbhatt H; Rosenthal MA J Clin Neurosci; 2015 Dec; 22(12):1889-94. PubMed ID: 26279503 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Twelves C; Campone M; Coudert B; Van den Bent M; de Jonge M; Dittrich C; Rampling R; Sorio R; Lacombe D; de Balincourt C; Fumoleau P; Ann Oncol; 2002 May; 13(5):777-80. PubMed ID: 12075748 [TBL] [Abstract][Full Text] [Related]
15. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S Oncology; 2012; 83(1):1-9. PubMed ID: 22688083 [TBL] [Abstract][Full Text] [Related]
16. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782 [TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079 [TBL] [Abstract][Full Text] [Related]